Abstract
Recurrent hepatitis C is a major cause of mortality in HIV/hepatitis C virus (HCV)-co-infected patients after orthotopic liver transplantation. We report sustained viral clearance in all four transplanted HIV/HCV-positive patients treated with pegylated interferon/ribavirin. Early therapy after HCV recurrence, tailoring treatment duration to the individual decline in HCV-RNA and the management of side effects are key factors for improved efficacy. At experienced centres interferon treatment is a valuable option for recurrent hepatitis C in HIV-positive patients.
MeSH terms
-
Administration, Oral
-
Antiviral Agents / administration & dosage*
-
Cohort Studies
-
Drug Therapy, Combination
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
Hepatitis C / complications
-
Hepatitis C / drug therapy*
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / surgery
-
Humans
-
Injections, Subcutaneous
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Liver Transplantation*
-
Polyethylene Glycols / administration & dosage
-
RNA, Viral / analysis
-
Recombinant Proteins
-
Recurrence
-
Ribavirin / administration & dosage
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
RNA, Viral
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a